KLK3 and neoplasm: PCWG3 has advised recording whether tumor progression was indicated by PSA alone, bone or node location, or bone plus node location, along with the proportion of patients who progress because this is prognostic [28]. PCWG3 is against activity-estimating endpoints in early-phase trials (such as declines in PSA) where the objective is to demonstrate sufficient antitumor activity to justify further study.